Brugen af Efient til patienter med øget risiko for blødning bør derfor kun overvejes, når fordelene i form af forebyggelse af iskæmiske tilfælde vurderes at opveje risikoen for alvorlige blødninger.
Therefore, the use of Efient in patients at increased risk of bleeding should only be considered when the benefits in terms of prevention of ischaemic events are deemed to outweigh the risk of serious bleedings.